Chenomx Inc.
Presenter: Neil Taylor, President & CEO
Company Profile
Chenomx Inc. (“Chenomx”) is a life sciences company developing a technology platform that will become the standard for complex mixture analysis in a broad number of applications. Chenomx offers a unique and revolutionary technology designed to improve the speed and accuracy of analyzing chemical mixtures. Chenomx’s first commercial application is in the area of Personalized Medicine. Customers use Chenomx’s technology platform for the analysis of bio-fluids to make scientific discoveries, to identify known disease markers and to develop diagnostic tests. Chenomx’s technology platform assists in understanding the relationship between health, disease and toxicology.
Chenomx believes Personalized Medicine can improve health: with diagnostic tests providing new information for physicians and patients, with new therapies that are patient specific, and by accelerating the drug approval process. Chenomx’s technology platform assists the advancement of Personalized Medicine.
Chenomx’s technology platform is fast, accurate, reliable and allows for robust analysis applications. Chenomx’s customers include: Sanofi Aventis, Glaxo Smith Kline, Astellas, Abbott Laboratories, Harvard University, University of Cambridge, the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency.
“Our metabolomics project has been greatly aided by the use of Chenomx software, specifically for the identification of metabolites and potential markers in a complex cell extract NMR spectra. We highly recommend its use for such applications.” Gregory J. Heffron - Director, Harvard Medical School NMR Facility
Moving Forward
Chenomx has been successful in establishing its technology platform with institutional and pharmaceutical researchers. Patent protection, early sales revenue, significant alliances and acceptance of the value added from Chenomx’s technology platform has set the stage for further growth. Expansion will leverage early acceptance of Chenomx’s technology platform beyond the research community, increase revenues, move the company closer to profitability and accelerate the development of diagnostic tests.
Highlights
• Revolutionary and patented technology
• Traction: strong client base in the research and pharmaceutical R&D community
• Strongly aligned with Varian, Inc., the largest NMR manufacturer in North America
• Managed growth from R&D to Clinical Trials to Diagnostics
• Strong competitive position due to patent protection, technology lead, high cost-to-enter and significant alliances
• Track record and early revenue to validate the concept and product
• Multiple revenue streams
Presenter Biography
Mr. Taylor is a businessman and developer of industrial software products. Founder of Taylor Industrial Software Ltd., a company which started in Edmonton with a staff of one and eventually employed over 100 personnel in the U.S. and Canada, and selling software products throughout the world. In 1996, Taylor Industrial merged with U.S.-based Total Control Products Inc. which obtained a NASDAQ listing in 1997. In 1998, Total Control was acquired by GE Fanuc Automation North America Inc., the industrial automation arm of General Electric Company. Mr. Taylor left Total Control in 1998.
Contact
Neil Taylor, President (ntaylor@chenomx.com, (780) 732-4551)
Chenomx, Inc.
#800, 10050 – 112 Street
Edmonton, Alberta T5K 2J1
www.chenomx.com